Literature DB >> 27511853

Pulsed Radiation Therapy With Concurrent Cisplatin Results in Superior Tumor Growth Delay in a Head and Neck Squamous Cell Carcinoma Murine Model.

Kurt Meyer1, Sarah A Krueger1, Jonathan L Kane1, Thomas G Wilson1, Alaa Hanna1, Mohamad Dabjan1, Katie M Hege1, George D Wilson1, Inga Grills1, Brian Marples2.   

Abstract

PURPOSE: To assess the efficacy of 3-week schedules of low-dose pulsed radiation treatment (PRT) and standard radiation therapy (SRT), with concurrent cisplatin (CDDP) in a head and neck squamous cell carcinoma xenograft model. METHODS AND MATERIALS: Subcutaneous UT-SCC-14 tumors were established in athymic NIH III HO female mice. A total of 30 Gy was administered as 2 Gy/d, 5 d/wk for 3 weeks, either by PRT (10 × 0.2 Gy/d, with a 3-minute break between each 0.2-Gy dose) or SRT (2 Gy/d, uninterrupted delivery) in combination with concurrent 2 mg/kg CDDP 3 times per week in the final 2 weeks of radiation therapy. Treatment-induced growth delays were defined from twice-weekly tumor volume measurements. Tumor hypoxia was assessed by (18)F-fluoromisonidazole positron emission tomography imaging, and calculated maximum standardized uptake values compared with tumor histology. Tumor vessel density and hypoxia were measured by quantitative immunohistochemistry. Normal tissues effects were evaluated in gut and skin.
RESULTS: Untreated tumors grew to 1000 mm(3) in 25.4 days (±1.2), compared with delays of 62.3 days (±3.5) for SRT + CDDP and 80.2 days (±5.0) for PRT + CDDP. Time to reach 2× pretreatment volume ranged from 8.2 days (±1.8) for untreated tumors to 67.1 days (±4.7) after PRT + CDDP. Significant differences in tumor growth delay were observed for SRT versus SRT + CDDP (P=.04), PRT versus PRT + CDDP (P=.035), and SRT + CDDP versus PRT + CDDP (P=.033), and for survival between PRT versus PRT + CDDP (P=.017) and SRT + CDDP versus PRT + CDDP (P=.008). Differences in tumor hypoxia were evident by (18)F-fluoromisonidazole positron emission tomography imaging between SRT and PRT (P=.025), although not with concurrent CDDP. Tumor vessel density differed between SRT + CDDP and PRT + CDDP (P=.011). No differences in normal tissue parameters were seen.
CONCLUSIONS: Concurrent CDDP was more effective in combination PRT than SRT at restricting tumor growth. Significant differences in tumor vascular density were evident between PRT and SRT, suggesting a preservation of vascular network with PRT.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27511853     DOI: 10.1016/j.ijrobp.2016.04.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results.

Authors:  Tugce Kutuk; Ranjini Tolakanahalli; Nicole C McAllister; Matthew D Hall; Martin C Tom; Muni Rubens; Haley Appel; Alonso N Gutierrez; Yazmin Odia; Alexander Mohler; Manmeet S Ahluwalia; Minesh P Mehta; Rupesh Kotecha
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

2.  Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer.

Authors:  George D Wilson; Thomas G Wilson; Alaa Hanna; Mohamad Dabjan; Katie Buelow; John Torma; Brian Marples; Sandra Galoforo
Journal:  Clin Transl Radiat Oncol       Date:  2020-11-08

3.  Radiomic analysis using contrast-enhanced CT: predict treatment response to pulsed low dose rate radiotherapy in gastric carcinoma with abdominal cavity metastasis.

Authors:  Zhen Hou; Yang Yang; Shuangshuang Li; Jing Yan; Wei Ren; Juan Liu; Kangxin Wang; Baorui Liu; Suiren Wan
Journal:  Quant Imaging Med Surg       Date:  2018-05

4.  Use of Pulsed Low-Dose Rate Radiotherapy in Refractory Malignancies.

Authors:  Jing Yan; Ju Yang; Yang Yang; Wei Ren; Juan Liu; Shanbao Gao; Shuangshuang Li; Weiwei Kong; Lijing Zhu; Mi Yang; Xiaoping Qian; Baorui Liu
Journal:  Transl Oncol       Date:  2018-01-04       Impact factor: 4.243

5.  Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy: Study protocol for a prospective multi-center phase II trial.

Authors:  Jie Li; Zhenhua Zhao; Guobo Du; Tangzhi Dai; Xuhai Zhen; Hongwei Cai; Dongbiao Liao; Miao Xiang; Yixue Wen; Lidan Geng; Xiyue Yang; Gang Feng; Yu Zhang; Jie Bai; Lei Liu; Xiaobo Du
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

6.  Analysing Tumour Growth Delay Data from Animal Irradiation Experiments with Deviations from the Prescribed Dose.

Authors:  Leonhard Karsch; Elke Beyreuther; Doreen Eger Passos; Jörg Pawelke; Steffen Löck
Journal:  Cancers (Basel)       Date:  2019-08-31       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.